Clinical Trial Search

Primary: Dose Limiting Toxicity — 0; 0; 0 Participants

Primary: Number of Patients With DLTs — 0; 2; 1; 0 Participants

Primary: Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up. — 6.7 months

Primary: Calculation of M Scores and HCC Probability Scores — 1.113; 1.159; 1.797; 1.707 units on a scale

Primary: Number of Subjects With Overall Survival — 16; 4; 34; 24 Participants — p=0.536

Primary: Response Rate by Recist Criteria — 6 participants

Primary: Time to Disease Progression — 8 months

Primary: Time to Progression (TTP) — 164; 112 days

Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM

Primary: Phase I: Maximum Tolerated Dose (MTD) of TRC105 When Given With Standard-dose Sorafenib for Hepatocellular Cancer (HCC) — 15 mg/kg

Primary: Phase 1b: Number of Participants Experiencing Dose Limiting Toxicity — 0; 0; 0 Participants

Primary: Progression Free Survival (PFS) Rate at 6 Months Per Independent Response Review Committee (IRRC) in Cohort A — 22.4 Percent of participants

Primary: Overall Survival — 289; 259 Days

Primary: Tumor Response — 0; 7; 47; 11 Participants

Primary: Rate of Adverse Events (AE) ≥ Grade 3 (CTCAE 5.0) Excluding Palmar-plantar Erythrodysesthesia — 16 Participants

Primary: Disease Control Rate (DCR) at 16 Weeks for Patients Treated With Guadecitabine After Failure of Sorafenib — 25.0; 24.4 percentage of patients

Primary: Progression-Free Survival(PFS) — 5.7; 2.7 months — p=<0.001

Primary: Number of Adverse Events — 12; 2; 8; 4 events

Primary: Number of Participants Who Remained Free of Progression at the 27th Week. — 21 participants — p=0.0006

Primary: Safety Run-in Sub-study: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 8; 1 Participants

Primary: Overall Survival (OS) — 324; 241 days — p=0.00583

Primary: Maximum Tolerated Dose in Phase I — 200; 200 mg

Primary: Time to Tumor Progression (TTP) for TRC105 in Hepatocellular Carcinoma (HCC). — 12 Weeks

Primary: 6 Month Progression Free Survival (PFS) — 2.8; NA Months

Primary: Phase 1b: Number of Participants Experiencing Dose Limiting Toxicity (DLT) According to National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) for Adverse Events…

Primary: To Assess the Safety and Tolerability of Itacitinib in Patients With HCC: Adverse Events — 14 Participants

Primary: Change in Serum AFP Levels — -1.928; 5.855 ng/mL — p=0.160

Primary: Incidence of Treatment-emergent Adverse Events (Safety and Tolerability) — 15 Participants

Primary: Disease Control Rate (DCR) — 0; 0; 9 Participants

Primary: Number of Subjects Experiencing Adverse Events — 2 participants